Vivos Therapeutics (VVOS) Other Accumulated Expenses (2022 - 2026)

Vivos Therapeutics (VVOS) has 5 years of Other Accumulated Expenses data on file, last reported at $150000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 77.68% year-over-year to $150000.0 in Q1 2026; TTM through Mar 2026 was $150000.0, a 77.68% decrease from a year earlier, with the FY2025 full-year figure at $175000.0, up 75.0% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $150000.0, down from $175000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for VVOS reached as high as $1.0 million in Q2 2025 and fell as low as $100000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $327625.0 across 5 years, with a median of $198500.0 in 2023.
• Across the five-year window, Other Accumulated Expenses soared 572.19% in 2025 and tumbled 77.68% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $145000.0 in 2022, then surged by 36.55% to $198000.0 in 2023, then plunged by 49.49% to $100000.0 in 2024, then soared by 75.0% to $175000.0 in 2025, then dropped by 14.29% to $150000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $150000.0 in Q1 2026, $175000.0 in Q4 2025, and $987000.0 in Q3 2025.